Beta We are building this new website to better deliver information. Learn more about this site.
Pregnancy Care Guidelines

31 Haemoglobin disorders

While identifying parents who are carriers for haemoglobin disorders before conception is preferable, discussing testing and the implications of carrier status early in pregnancy enables women and their partners to make informed choices.

31.1 Background

Mutation of the genes that contain the information for cells to make haemoglobin can result in low or absent production of normal adult haemoglobin (thalassaemias) or changes in the structure of the haemoglobin protein (haemoglobin variants such as sickle cell disease).

When babies inherit mutated globin genes from both parents, they may be affected by or be a carrier for a haemoglobin disorder. It is very unlikely that the baby will be affected when only one parent is a carrier for a haemoglobin disorder, but the baby may be a carrier.

31.1.1 Prevalence of haemoglobin disorders

  • Globally, over 330,000 affected infants are born each year (83% sickle cell disorders and 17% thalassaemias), around 7% of pregnant women are carriers of haemoglobin disorders and over 1% of couples are at risk (Modell & Darlison 2008).
  • The risk of being a carrier for a haemoglobin disorder varies with ethnicity (Gaff et al 2007):
    • alpha thalassaemia is most prevalent among people of Chinese and South-East Asian origin but occurs in many other ethnic groups, including people from Southern European countries, the Middle East, the Indian subcontinent, Pakistan, Africa, the Pacific Islands and New Zealand (Maori)
    • beta thalassaemia is prevalent among people from the Middle East, Southern Europe, Indian subcontinent, Central and South-East Asia and Africa
    • sickle cell disease is seen in many populations including people from Africa, the Middle East, Southern Europe, India, Pakistan, South America and the Caribbean.
  • In Australia (Gaff et al 2007):
    • alpha thalassaemia has been identified in some Aboriginal and Torres Strait Islander communities in the Northern Territory and northern Western Australia
    • sickle cell disease has been most commonly seen in individuals of Southern European and Middle-Eastern origin (especially Lebanese and Turkish) but is becoming more prevalent with increasing immigration from sub-Saharan Africa and the Indian subcontinent.

31.1.2 Risks associated with haemoglobin disorders

  • Thalassaemias vary in severity depending on the number of faulty globin genes (CGE 2007). Symptoms range from mild anaemia to severe anaemia that requires blood transfusions lifelong. A baby with alpha thalassaemia, if born alive, does not usually survive for long after the birth (Bart’s hydrops fetalis).
  • Sickle cell anaemia is characterised by chronic anaemia, bone and chest pain, organ damage, failure to thrive, repeated infections and painful swelling of the hands and feet (CGE 2007).

31.2 Testing for haemoglobin disorders

In Australia, RANZCOG recommends that local policies for testing for haemoglobin disorders take into account the ethnic mix of women tested (RANZCOG 2009).

31.2.1 Discussing ethnicity

It is not possible to assume ethnicity from country of birth or surname. More information can be obtained by asking women where their parents, grandparents or great-grandparents were born (Gaff et al 2007). An RCT in the United Kingdom found that a questionnaire listing a range of ethnicities was more effective in ascertaining ancestry than a simple question about ethnic origins outside the United Kingdom (Dyson et al 2006).

31.2.2 Test

The RANZCOG recommends that mean corpuscular volume (MCV) and mean corpuscular haemoglobin (MCH) be tested in all women (RANZCOG 2009). A small study found that MCV had a sensitivity of 92.9% and specificity of 83.9% for thalassaemia testing (Sirichotiyakul et al 2005).

Testing using MCV and MCH will identify some but not all carriers of alpha and beta globin gene changes. It should be noted that some beta globin gene changes (eg sickle cell trait) result in normal red cell indices and detection relies on haemoglobin electrophoresis.

31.2.3 Harms and benefits of testing

Narrative reviews indicate testing of women at increased risk of being carriers for haemoglobin disorders can identify couples who are both carriers and have a 25% risk of having a pregnancy with a significant genetic disorder for which antenatal diagnosis is possible (Langlois et al 2008). No studies identified harms associated with testing. One study found that being well informed about haemoglobin disorders may reduce anxiety in women who are subsequently identified as carriers (Brown et al 2011).

31.2.4 Timing of testing

Narrative reviews suggest that the ideal time for testing for haemoglobin disorders would be preconception (Gaff et al 2007). If this is not possible, testing should take place as early as possible in pregnancy. Studies have found that when testing was offered in primary care (eg as part of the pregnancy confirmation visit), women were tested at an earlier gestation (Thomas et al 2005; Dormandy et al 2010a; Dormandy et al 2010b).

31.2.5 Cost-effectiveness of testing

Studies have found that antenatal testing in populations with a high prevalence of haemoglobin disorders is cost effective (Leung et al 2004; Koren et al 2009). While testing at confirmation of pregnancy may require additional resources, it increases the number of women tested by 10 weeks gestation (Dormandy et al 2010a). Cost-effectiveness studies support testing of fathers after a woman has been identified as a carrier for a haemoglobin disorder rather than on confirmation of pregnancy (Dormandy et al 2010a; Bryan et al 2011).

Recommendation

  • Consensus-based
  • XXXVIII

As early as possible in pregnancy, routinely provide information about haemoglobin disorders and offer testing (full blood count). 

Approved by NHMRC in June 2014; expires June 2019

Recommendation

  • Practice point
  • VV

Consider offering ferritin testing and haemoglobin electrophoresis as part of initial testing to women from high-risk population groups. 

Approved by NHMRC in June 2014; expires June 2019

31.3 Further investigations

Further testing is recommended for women who (Gaff et al 2007):

  • have a MCV ≤80 fL and/or MCH ≤27 pg
  • have a family history of anaemia, thalassaemia or other abnormal haemoglobin variant and/or
  • originate from high-risk population groups: Southern Europe, Middle East, Africa, China, South-East Asia, the Indian subcontinent, Pacific Islands, New Zealand (Maori), South America and some Aboriginal and Torres Strait Islander communities in northern Western Australia and the Northern Territory.

Relevant tests include:

  • ferritin testing to exclude iron-deficiency anaemia
  • electrophoresis or high pressure liquid chromatography, to identify haemoglobin variants (red cell indices can be normal in carriers for some haemoglobin disorders).

Further studies (eg DNA analysis) may be carried out for final clarification of the carrier state.

Diagnosis of an affected baby is generally by chorionic villus sampling, usually in the first trimester (Gaff et al 2007). A small study (n=777) found that ultrasound markers (middle cerebral artery peak systolic velocity plus fetal cardiothoracic ratio) had a low false positive rate in diagnosing alpha thalassaemia (Leung et al 2010).

31.4 Discussing haemoglobin disorders

Providing women with sufficient information about haemoglobin disorders enables informed choices about testing (Brown et al 2011). Discussion to inform a woman’s decision-making about testing for haemoglobin disorders should take place before testing and include:

  • people can be carriers of haemoglobin disorders without being affected by the condition or may be only mildly affected
  • people from some ethnic groups are more likely to be carriers of or affected by haemoglobin disorders
  • if only one parent is a carrier, it is unlikely that the baby will be affected but he or she may be a carrier
  • if both parents are carriers for a haemoglobin disorder, there is a chance that the baby will be affected by the condition
  • there are implications for the health of an affected baby.

31.5 Practice summary: haemoglobin disorders 

When

At the first antenatal visit.

Who

  • Midwife
  • GP
  • obstetrician
  • Aboriginal and Torres Strait Islander Health Practitioner
  • Aboriginal and Torres Strait Islander Health Worker
  • multicultural health worker.

What

  • Discuss the reasons for testing for haemoglobin disorders
    Explain that when both parents are carriers for a haemoglobin disorder, the baby may be affected (1 in 4 chance) with possible serious consequences. 
  • Offer testing to fathers
    If a woman is identified as a carrier of a significant haemoglobin disorder, testing should be offered to the father. Other family members may also benefit from an offer of testing. 
  • Take a holistic approach
    Arrange counselling for parents when both are identified as carriers of haemoglobin disorders. 
  • Document and follow-up
    Ensure that women receive timely notice of the results of any tests carried out. Have a system in place so that women identified as carriers of haemoglobin disorders receive ongoing support.

31.6 Resources

References

  • Brown K, Dormandy E, Reid E et al (2011) Impact on informed choice of offering antenatal sickle cell and thalassaemia screening in primary care: a randomized trial. J Med Screen 18(2): 65–75.
  • Bryan S, Dormandy E, Roberts T et al (2011) Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study. Br J Gen Pract 61(591): e620–27.
  • CGE (2007) Fact Sheet 34: Thalassaemias and Sickle Cell Disease. Sydney: NSW Health Centre for Genetics Education.
  • Dormandy E, Bryan S, Gulliford MC et al (2010a) Antenatal screening for haemoglobinopathies in primary care: a cohort study and cluster randomised trial to inform a simulation model. The Screening for Haemoglobinopathies in First Trimester (SHIFT) trial. Health Technol Assess 4(20).
  • Dormandy E, Gulliford M, Bryan S et al (2010b) Effectiveness of earlier antenatal screening for sickle cell disease and thalassaemia in primary care: cluster randomised trial. BMJ 341(oct05 2): c5132.
  • Dyson SM, Culley L, Gill C et al (2006) Ethnicity questions and antenatal screening for sickle cell/thalassaemia [EQUANS] in England: a randomised controlled trial of two questionnaires. Ethn Health 11(2): 169–89.
  • Gaff C, Newstead J, Saleh M (2007) Haemoglobinopathies. In: Genetics in Family Medicine: The Australian Handbook for General Practitioners. Ed. Commonwealth of Australia: Biotechnology Australia.
  • Koren A, Zalman L, Palmor H et al (2009) Sickle cell anemia in northern Israel: screening and prevention. Isr Med Assoc J 11(4): 229–34.
  • Langlois S, Ford JC, Chitayat D et al (2008) Carrier screening for thalassemia and hemoglobinopathies in Canada. J Obstet Gynaecol Can 30(10): 950–71.
  • Leung KY, Lee CP, Tang MH et al (2004) Cost-effectiveness of prenatal screening for thalassaemia in Hong Kong. Prenat Diagn 24(11): 899–907.
  • Leung KY, Cheong KB, Lee CP et al (2010) Ultrasonographic prediction of homozygous alpha0-thalassemia using placental thickness, fetal cardiothoracic ratio and middle cerebral artery Doppler: alone or in combination? Ultrasound Obstet Gynecol 35(2): 149–54.
  • Modell B & Darlison M (2008) Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008(6): 480–87.
  • RANZCOG (2009) Pre-pregnancy Counselling and Routine Antenatal Assessment in the Absence of Pregnancy Complications (C-Obs-3). Melbourne: Royal Australia and New Zealand College of Obstetricians and Gynaecologists.
  • Sirichotiyakul S, Maneerat J, Sa-nguansermsri T et al (2005) Sensitivity and specificity of mean corpuscular volume testing for screening for alpha-thalassemia-1 and beta-thalassemia traits. J Obstet Gynaecol Res 31(3): 198–201.
  • Thomas P, Oni L, Alli M et al (2005) Antenatal screening for haemoglobinopathies in primary care: A whole system participatory action research project. Brit J General Pract 55(515): 424–28.
Last updated: 
21 November 2018